Erlotinib – Targeted Therapy

Erlotinib hydrochloride is the active ingredient belonging to a group of targeted anticancer drugs known as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Erlotinib blocks EGFR activity, leading to the inhibition of cancer cell growth and proliferation. It is used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations and pancreatic cancer in patients with progressive disease after chemotherapy. Erlotinib is taken orally in tablet form and is part of targeted therapy aimed at more precise and effective suppression of cancer processes with fewer side effects compared to traditional chemotherapy.